H.C. Wainwright Initiates a Buy Rating on Revance Therapeutics (RVNC)


In a report released today, Douglas Tsao from H.C. Wainwright initiated coverage with a Buy rating on Revance Therapeutics (RVNC) and a price target of $25. The company’s shares closed yesterday at $17.78, close to its 52-week low of $16.56.

Tsao said:

“Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%.”

According to TipRanks.com, Tsao is ranked #2794 out of 5163 analysts.

Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.17.

See today’s analyst top recommended stocks >>

The company has a one-year high of $34.55 and a one-year low of $16.56. Currently, Revance Therapeutics has an average volume of 443.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts